Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enhabit, Inc. filings document formal disclosures for a public home health and hospice care provider. Recent reports include 8-K material-event disclosures, Regulation FD materials, operating and financial results, risk-factor updates, shareholder voting matters and capital-structure information.
The company’s SEC record also covers material definitive agreements, including credit facilities and related debt terms, governance matters such as officer transitions, and litigation-related disclosures involving claims connected to its home health and hospice business history. These filings frame Enhabit’s regulatory reporting around healthcare operations, financing arrangements, corporate governance and stockholder matters.
Enhabit, Inc. (EHAB) Form 4 filing – insider purchase
Director Charles M. Elson reported an open-market acquisition of 15,773 common shares on 06/26/2025 at $9.51 per share (Transaction Code "A"). After the transaction, his direct beneficial ownership stands at 72,494 shares. No derivative security trades or dispositions were disclosed, and there is no indication the trade was executed under a Rule 10b5-1 plan.
The purchase increases the director’s equity exposure and can be viewed as a personal vote of confidence in Enhabit’s outlook. No other material events or financial metrics were included in the filing.
Enhabit (NYSE:EHAB) filed a Form 4 on 28 June 2025 reporting that director Tina L. Brown-Stevenson acquired 15,773 shares of common stock on 26 June 2025 at $9.51 per share (transaction code “A”). The purchase, valued at roughly $150 thousand, lifts her direct beneficial ownership to 52,698 shares, an increase of about 30% versus her pre-transaction holdings. No shares were sold and no derivative securities were involved. The filing was signed by Attorney-in-Fact Sarah W. Braley on 27 June 2025 and contains standard Section 16 certifications.
Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Jeffrey Bolton purchased 15,773 common shares on 26 Jun 2025 at $9.51 each. The acquisition lifted his direct ownership to 123,395 shares, approximately a 15 % increase from his pre-transaction position. No dispositions or derivative securities were reported and the filing does not note any Rule 10b5-1 trading plan. Because Form 4 reports relate solely to insider activity, the document contains no financial statements, risk factors or operational updates.
Enhabit (NYSE:EHAB) filed an 8-K reporting results of its 26 June 2025 annual meeting. Shareholders approved the 2025 Equity & Incentive Compensation Plan, reserving up to 3.3 million shares (≈6.5% of the 50.6 million outstanding) for options, RSUs and performance awards. The plan, administered by the Compensation & Human Capital Committee, includes a $750k annual cap on non-employee director pay and allows performance metrics spanning EBITDA, revenue and quality-of-care. All 10 directors were re-elected, PwC was ratified as auditor and the say-on-pay resolution passed. Support for the equity plan was strong at 31.0 M for vs 0.4 M against. While the plan aligns incentives, it introduces potential dilution and higher stock-based compensation expense.
Enhabit, Inc. (ticker EHAB) has filed a Form S-8 with the SEC to register 3,289,042 shares of common stock for issuance under its newly approved 2025 Equity and Incentive Compensation Plan. The plan was authorized by shareholders at the 2025 Annual Meeting held on June 26, 2025. The filing incorporates the company’s most recent FY-2024 Form 10-K, Q1-2025 Form 10-Q, and prior descriptions of common stock by reference, ensuring that future periodic reports will automatically update the prospectus information.
The document outlines standard Delaware indemnification provisions for directors and officers, confirms the existence of D&O insurance, and lists required exhibits—most notably the full plan text (Exhibit 4.3) and an auditor consent from PwC (Exhibit 23.1). No new financial performance data, earnings guidance, or transactional details are disclosed, and the filing does not alter previously reported financial statements.
For investors, the primary implication is potential dilution from future equity grants as the registered shares become available for employee compensation. The filing is routine for public companies implementing stock-based incentive programs and does not, by itself, signal a change in the company’s operating outlook.